skip to content

Wellcome - MRC Cambridge Stem Cell Institute

 

107-Hodson-2017Dr Daniel Hodson

Deciphering the genomics of B cell lymphomas

Email: djh1002@cam.ac.uk

Laboratory: Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre

Departmental Affiliation: Haematology

 

Biography

Daniel Hodson studied Medicine at Cambridge University and then clinical medicine at Oxford University. He subsequently trained as a clinical haematologist with a special interest in lymphoid malignancies. During his haematology training he undertook a PhD in molecular immunology at the Babraham Institute in Cambridge under the supervision of Dr Martin Turner, where he studied the contribution of post-transcriptional regulation to the normal lymphocyte development. In 2010 he moved to the National Cancer Institute, USA, as a post-doctoral fellow in the lab of Dr Lou Staudt, where he developed expertise in the application of functional genomics to the study of B cell lymphomas. In 2015 he returned to Cambridge as a Medical Research Council Clinician Scientist and group leader in the SCI and the Department of Haematology. His group researches the molecular mechanisms that underlie lymphomagenesis. Dr Hodson also holds an honorary consultant contract in the Haematology Department at Addenbrooke’s Hospital.

 

Funding

CRUK, Kay Kendal Leukaemia Fund, Addenbrooke's Charitable Trust, The Evelyn Trust, MRC

 

The unique and dangerous life of the B cell

 

Research

Normal B lymphocytes progress through a series of developmental stages that begin with the haematopoietic stem cell. Progression through each of these stages is tightly controlled at both the transcriptional and post-transcriptional levels. Genetic alterations and mutations, which can occur at any stage from the haematopoietic stem cell to the post-germinal centre B cell, can lead to loss of this normal regulation and subsequently to the development of lymphoid malignancies such as non-Hodgkin Lymphoma (NHL), the 6th commonest form of human cancer. Understanding how these genetic alterations corrupt cell fate choices at each stage of lymphocyte development will be the key to identifying cellular pathways that can be therapeutically targeted. My group has developed novel cell culture models to study the effects of introducing these genetic alterations into healthy human B cells. In particular, we are interested to study how these genetic alterations lead to the transformation of normal B cells into malignant lymphoma cells. We use a variety of techniques including exome and RNA sequencing, ctDNA analysis, ribosome profiling, iCLIP, single cell sequencing, CRISPR, and xenografts to identify the mechanistic contribution of these mutations to lymphomagenesis and the implications this has for the treatment and monitoring of patients.   

 

850 Hodson group 2 1ratio

 

Group Members

Miriam Di Re, Jane Gao, Jade Gong, Joanna Krupka, Hendrik Runge, Rachel Fenner, Stamatia Vorri, Laura Everton, and Sean Corcoran                

 

Key Publications